abstract |
The present invention focuses on anti-angiogenic therapy for the treatment of ovarian cancer. In general, the present invention contemplates the treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the present invention contemplates the use of anti-VEGF antibodies, preferably in combination with one or more other anti-tumor therapeutics for the treatment of ovarian cancer, in the treatment of human patients susceptible to or diagnosed with cancer. |